X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (52) 52
index medicus (48) 48
male (37) 37
cancer (36) 36
oncology (36) 36
chemotherapy (30) 30
aged (29) 29
middle aged (26) 26
prostate cancer (26) 26
metastasis (24) 24
treatment outcome (23) 23
urology & nephrology (23) 23
care and treatment (22) 22
hematology, oncology and palliative medicine (16) 16
adult (15) 15
antineoplastic combined chemotherapy protocols - therapeutic use (15) 15
female (15) 15
disease-free survival (14) 14
urology (14) 14
cancer therapies (13) 13
phase-ii trial (13) 13
research (13) 13
survival (13) 13
kaplan-meier estimate (12) 12
survival analysis (12) 12
docetaxel (11) 11
neoplasm staging (11) 11
aged, 80 and over (10) 10
antimitotic agents (10) 10
antineoplastic agents (10) 10
antineoplastic agents - therapeutic use (10) 10
double-blind method (10) 10
medical colleges (10) 10
prognosis (10) 10
carcinoma (9) 9
carcinoma, renal cell - drug therapy (9) 9
carcinoma, transitional cell - drug therapy (9) 9
kidney neoplasms - drug therapy (9) 9
men (9) 9
oncology, experimental (9) 9
prostatic neoplasms - pathology (9) 9
transitional-cell carcinoma (9) 9
urinary bladder neoplasms - drug therapy (9) 9
urothelial carcinoma (9) 9
analysis (8) 8
article (8) 8
bladder cancer (8) 8
bone neoplasms - secondary (8) 8
kidney neoplasms - pathology (8) 8
patients (8) 8
prednisone (8) 8
urologic neoplasms - drug therapy (8) 8
androgen antagonists - therapeutic use (7) 7
clinical trials (7) 7
double-blind (7) 7
drug therapy (7) 7
gemcitabine (7) 7
mitoxantrone plus prednisone (7) 7
prostatic neoplasms - drug therapy (7) 7
risk factors (7) 7
sunitinib (7) 7
urinary bladder neoplasms - pathology (7) 7
abiraterone acetate (6) 6
development and progression (6) 6
endothelial growth-factor (6) 6
health aspects (6) 6
medicine, general & internal (6) 6
neoplasm metastasis (6) 6
pazopanib (6) 6
phase-iii trial (6) 6
product development (6) 6
proportional hazards models (6) 6
prostatic neoplasms - mortality (6) 6
prostatic neoplasms, castration-resistant - drug therapy (6) 6
therapy (6) 6
urologic neoplasms - pathology (6) 6
abridged index medicus (5) 5
adjuvant chemotherapy (5) 5
androgen antagonists - adverse effects (5) 5
androgens (5) 5
antineoplastic agents, hormonal - therapeutic use (5) 5
antitumor-activity (5) 5
bone neoplasms - drug therapy (5) 5
carcinoma, renal cell - mortality (5) 5
carcinoma, renal cell - secondary (5) 5
carcinoma, transitional cell - secondary (5) 5
cisplatin - administration & dosage (5) 5
cisplatin-based chemotherapy (5) 5
cooperative-oncology-group (5) 5
corticosteroids (5) 5
drug dosages (5) 5
follow-up studies (5) 5
hospitals (5) 5
immunotherapy (5) 5
interferon-alpha (5) 5
kidney neoplasms - mortality (5) 5
medical prognosis (5) 5
medical research (5) 5
metastases (5) 5
neoadjuvant chemotherapy (5) 5
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Lancet Oncology, ISSN 1470-2045, 2015, Volume 16, Issue 2, pp. 152 - 160
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 12, pp. 1210 - 1217
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 3, pp. 286 - 296
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 10, pp. 1147 - 1156
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 8, pp. 827 - 837
Journal Article
by Petrylak, Daniel and Petrylak, Daniel P and de Wit, Ronald and Chi, Kim Nguyen and Chi, Kim N and Drakaki, Alexandra and Sternberg, Cora N and Nishiyama, Hiroyuki and Castellano, Daniel and Hussain, Syed and Fléchon, Aude and Bamias, Aristotelis and Yu, Evan Y and van der Heijden, Michiel S and Matsubara, Nobuaki and Alekseev, Boris and Necchi, Andrea and Géczi, Lajos and Ou, Yen-Chuan and Coskun, Hasan Senol and Su, Yu-Li and Su, Wen-Pin and Hegemann, Miriam and Percent, Ivor and Percent, Ivor J and Lee, Yun-Gyoo and Lee, Hyo Jin and Lee, Jae-Lyun and Tucci, Marcello and Semenov, Andrey and Laestadius, Fredrik and Peer, Avivit and Tortora, Giampaolo and Safina, Sufia Z and Safina, Sufia and del Muro, Xavier Garcia and Rodriguez-Vida, Alejo and Cicin, Irfan and Harputluoglu, Hakan and Widau, Ryan C and Liepa, Astra M and Walgren, Richard A and Hamid, Oday and Zimmermann, Annamaria H and Bell-McGuinn, Katherine M and Powles, Thomas and Wong, Suet-Lai Shirley and Tan, Thean Hsiang and Hovey, Elizabeth Jane and Clay, Timothy Dudley and Ng, Siobhan Su Wan and Rutten, Annemie and Machiels, Jean-Pascal and Dumez, Herlinde and Cheng, Susanna Yee-Shan and Ferrario, Cristiano and Sengeloev, Lisa and Jensen, Niels Viggo and Thibault, Constance and Laguerre, Brigitte and Joly, Florence and Flechon, Aude and Culine, Stéphane and Becht, Catherine and Niegisch, Günter and Stöckle, Michael and Grimm, Marc-Oliver and Gakis, Georgios and Schultze-Seemann, Wolfgang and Kalofonos, Haralambos and Mavroudis, Dimitrios and Papandreou, Christos and Karavasilis, Vasilis and Révész, Janos and Geczi, Lajos and Rosenbaum, Eli and Leibowitz-Amit, Raya and Kejzman, Daniel and Sarid, David and Scagliotti, Giorgio Vittorio and Bracarda, Sergio and Massari, Francesco and Osawa, Takahiro and Miyajima, Naoto and Shinohara, Nobuo and Fukuta, Fumimasa and Ohyama, Chikara and Obara, Wataru and Yamashita, Shinichi and Tomita, Yoshihiko and Kawai, Koji and Fukasawa, Satoshi and Oyama, Masafumi and Yonese, Junji and Nagata, Masayoshi and Uemura, Motohide and Nishimura, Kazuo and Kawakita, Mutsushi and Tsunemori, Hiroyuki and Hashine, Katsuyoshi and ... and RANGE Study Investigators and RANGE study investigators
The Lancet, ISSN 0140-6736, 11/2017, Volume 390, Issue 10109, pp. 2266 - 2277
Few treatments with a distinct mechanism of action are available for patients with platinum-refractory advanced or metastatic urothelial carcinoma. We assessed... 
BLADDER-CANCER | MEDICINE, GENERAL & INTERNAL | 2ND-LINE THERAPY | TRANSITIONAL-CELL-CARCINOMA | CISPLATIN | DOXORUBICIN | METHOTREXATE | VINBLASTINE | OPEN-LABEL | COMBINATION | ENDOTHELIAL GROWTH-FACTOR | Carcinoma, Transitional Cell - mortality | Prognosis | Humans | Middle Aged | Male | Neoplasm Invasiveness - pathology | Urinary Bladder Neoplasms - pathology | Adult | Female | Urinary Bladder Neoplasms - mortality | Double-Blind Method | Risk Assessment | Docetaxel | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Urinary Bladder Neoplasms - drug therapy | Disease-Free Survival | Taxoids - administration & dosage | Carcinoma, Transitional Cell - pathology | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Internationality | Neoadjuvant Therapy - methods | Carcinoma, Transitional Cell - drug therapy | Survival Analysis | Aged | Neoplasm Staging | Antimitotic agents | Care and treatment | Carcinoma | Analysis | Clinical trials | Product development | Metastasis | Antineoplastic agents | Cancer | Cytotoxicity | Oncology | Patients | Cancer therapies | Metastases | Angiogenesis | Chemotherapy | Platinum | Medical prognosis | Ligands | Clinical medicine | Urothelial carcinoma | Vascular endothelial growth factor | Apoptosis
Journal Article
Lancet Oncology, ISSN 1470-2045, 2015, Volume 16, Issue 1, pp. 76 - 86
Summary Background Patients with muscle-invasive urothelial carcinoma of the bladder have poor survival after cystectomy. The EORTC 30994 trial aimed to... 
Hematology, Oncology and Palliative Medicine | ADJUVANT CHEMOTHERAPY | PLUS CISPLATIN | METAANALYSIS | NEOADJUVANT CHEMOTHERAPY | ONCOLOGY | DOXORUBICIN | METHOTREXATE | VINBLASTINE | CANCER | GEMCITABINE | Lymph Node Excision | Cystectomy - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carcinoma - mortality | Male | Vinblastine - administration & dosage | Cystectomy - adverse effects | Urothelium - pathology | Cisplatin - administration & dosage | Time Factors | Urinary Bladder Neoplasms - pathology | Female | Chemotherapy, Adjuvant | Carcinoma - pathology | Doxorubicin - administration & dosage | Carcinoma - drug therapy | Urinary Bladder Neoplasms - mortality | Drug Administration Schedule | Time-to-Treatment | Carcinoma - surgery | Deoxycytidine - administration & dosage | Europe | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Urinary Bladder Neoplasms - drug therapy | Urinary Bladder Neoplasms - surgery | Canada | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Methotrexate - administration & dosage | Urothelium - surgery | Neoplasm Staging | Urothelium - drug effects | Deoxycytidine - analogs & derivatives | Care and treatment | Chemotherapy | Carcinoma | Hospitals | Cancer
Journal Article